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We present the type-distribution of high-risk human papillomavirus (HPV) types in women with normal cytology (n¼1467),
adenocarcinoma in situ (ACIS) (n¼61), adenocarcinoma (n¼70), and squamous cell carcinoma (SCC) (n¼83). Cervical
adenocarcinoma and ACIS were significantly more frequently associated with HPV18 (ORMH 15.0; 95% CI 8.6–26.1 and 21.8; 95%
CI 11.9–39.8, respectively) than normal cytology. Human papillomavirus16 was only associated with adenocarcinoma and ACIS after
exclusion of HPV18-positive cases (ORMH 6.6; 95% CI 2.8–16.0 and 9.4; 95% CI 2.8–31.2, respectively). For SCC, HPV16 prevalence
was elevated (ORMH 7.0; 95% CI 3.9–12.4) compared to cases with normal cytology, and HPV18 prevalence was only increased
after exclusion of HPV16-positive cases (ORMH 4.3; 95% CI 1.6–11.6). These results suggest that HPV18 is mainly a risk factor for the
development of adenocarcinoma whereas HPV16 is associated with both SCC and adenocarcinoma.
British Journal of Cancer (2006) 94, 171–175. doi:10.1038/sj.bjc.6602915 www.bjcancer.com
Published online 13 December 2005
& 2006 Cancer Research UK
Keywords: cervix neoplasm; adenocarcinoma; squamous cell carcinoma; human papillomavirus; epidemiology; cohort study
                                         
Cervical carcinomas are unfortunate complications of longstand-
ing infections with high-risk types of human papillomavirus
(hrHPV) (Walboomers et al, 1999). Testing for hrHPV types
combined with cervical cytology becomes increasingly attractive as
data accumulate that a combined test increases the efficacy of
cervical screening programmes and triage policies for women with
both equivocal and normal cervical smears (Cuzick et al, 2003;
Khan et al, 2005). Possibly, even more efficient screening strategies
can be developed by selecting hrHPV types conferring a
preferential risk for the development of cervical cancer, and treat
these infections more aggressively. In order to assess the
preferential risk for cervical cancer and its precursors, type-
specific prevalence of hrHPV types in cancer cases should be
compared to type-specific prevalence in women without cancer. In
a meta-analysis of cervical squamous cell carcinomas (SCCs)
compared to high-grade squamous intraepithelial lesions, HPV16,
HPV18 and HPV45 appeared to display an elevated prevalence in
cervical cancer (Clifford et al, 2003a). A second meta-analysis
revealed that HPV16 and HPV18 are more prevalent in SCC than in
low-grade SIL (Clifford et al, 2005). However, a comparison with
hrHPV prevalence in women with normal cytology was not made,
hampering the translation of these findings to implementation of
type-specific hrHPV testing in population-based screening.
Recently in a cross-sectional study, we have demonstrated that
among the hrHPV types, HPV16 and HPV33 were significantly more
common in women with cervical intraepithelial neoplasia grade 2 or
more (XCIN2) than in women with normal cytology. However in
that study, cases of XCIN2 were retrieved from population-based
screening, and consequently, the prevalence of invasive carcinomas
as well as adenocarcinoma in situ (ACIS) was low.
In order to obtain a more comprehensive view on the change in
distribution from hrHPV infections without cytological abnorm-
alities to hrHPV prevalence in cervical cancer, we compared cross-
sectional screening data of women with normal cytology to
retrospectively collected cases of SCC, adenocarcinoma (AdCx)
and ACIS.
MATERIALS AND METHODS
Women with normal cytology
Women with normal cytology and a positive hrHPV test were
recruited from the POpulation-BAsed SCreening AMsterdam
(POBASCAM) trial. The POBASCAM trial is a population-based
randomised, controlled trial to evaluate the efficacy of screening
using hrHPV testing in conjunction with conventional cytology vs
cervical screening with conventional cytology only. This trial was
conducted within the regular Dutch cervical screening programme
in which women aged 30–60 years are screened cytologically with
a screening interval of 5 years (van Ballegooijen and Hermens,
2000). In the POBASCAM trial, details of which have been
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ydescribed elsewhere, conventional smears were taken using either
a Cervex brush or a cytobrush (Bulkmans et al, 2004). After taking
the smear, the brush was placed in a vial containing collection
medium for hrHPV testing. Cervical smears were then classified
according to the Dutch CISOE-A classification, which can be
translated to the Bethesda system (Solomon et al, 2002; Bulk et al,
2004).
Detection of hrHPV was performed by GP 5þ/6þ PCR enzyme
immunoassay, using a cocktail of 14 high-risk types, that is,
HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51,
HPV52, HPV56, HPV58, HPV59, HPV66 and HPV68 (Jacobs et al,
1997). All hrHPV-positive samples were typed by reverse line
blotting (van den Brule et al, 2002).
Between 1998 and 2002, a total of 44102 women were included
in the study. Of these women, 3.7% (n¼1576) were diagnosed with
a normal Pap test and a positive hrHPV test. Women who were
positive for hrHPV by GP5þ/6þ PCR but negative for reverse
line blot were excluded (n¼109), leaving 1467 women for the
analysis. All technicians were blinded to hrHPV status and
cytological diagnosis of the samples.
Cases with cervical carcinoma (in situ)
All cases of cervical carcinoma (in situ) were identified during the
course of previous studies (Zielinski et al, 2001, 2003). Cases with
ACIS and invasive AdCx of the cervix were enrolled from four
pathology departments in The Netherlands. In the period 1996–
2000, formalin-fixed specimens of 62 ACIS cases and 77 cases of
AdCx were identified that were adequate for hrHPV PCR analysis.
Cases with SCC were identified in a geographically defined region
of The Netherlands. Archival formalin-fixed material was collected
of 91 SCC cases from the period 1981 to 1998.
HrHPV detection was performed by GP5þ/6þ PCR as
described above. In addition, all GP5þ/6þ PCR-negative samples
were evaluated by E7 region type-specific PCR for the same 14
high-risk types in order to exclude that cases with hrHPV DNA
integrated in the GP5þ/6þ primer binding region were
diagnosed as hrHPV negative (Walboomers et al, 1999). Labora-
tory personnel unaware of the histological diagnosis performed
hrHPV determinations.
Of the cases with ACIS, one tested negative for hrHPV by both
PCR tests, and four cases tested positive only by type-specific E7
PCR. Seven of the 77 AdCx cases tested negative for hrHPV by
both tests, and seven tested positive only for type-specific E7 PCR.
Of the women with SCC, seven cases tested negative for hrHPV by
both assays and one case tested positive by type-specific E7 PCR
only, leaving 83 cases with SCC for analysis.
Statistical analysis
Differences in prevalence of hrHPV types for women with normal
cytology compared to women with cervical carcinoma were
examined using the Mantel–Haenszel common odds ratio (ORMH),
95% Confidence intervals (95% CI’s) were calculated. Statistical
significance was tested by Cochran’s Mantel–Haenszel test. Only
ORMH with values of 1.0 or higher are reported. Data were adjusted
in 5-year age categories (i.e., below 29 years, 29–33, 34–38, 39–43,
44–48, 49–53, 54–58, 59–61, and 61 years and over), matching
with age categories in nationwide screening. The presence of an
association between ORMH and age was tested by Breslow–Day’s
test of homogeneity. Variations in the prevalence of single and
multiple infections were assessed using w
2 analysis. Analyses were
performed separately for women with either single and multiple
infections or single infections only. Since HPV18 prevalence
heavily dominated in AdCx and ACIS, and HPV16 infections
dominated in both normal cytology and SCC, we also calculated
risk estimates after either discarding HPV16-positive cases, or
HPV18-positive cases, or both.
A potential source of bias may be that women with normal
cytology were matched with cases with cancer in the same 5-year
age category. As it takes at least 8–10 years to develop invasive
carcinoma of the cervix after infection with hrHPV, we repeated
the analyses matching cases with cancer with normal controls 10
years younger (van Oortmarssen and Habbema, 1995; Zielinski
et al, 2001; Berkhof et al, 2005). For these analyses, we included
women with normal cytology who were sampled during the
enrolment phase of the POBASCAM trial, but did not meet the age
criteria for population-based cervical screening (n¼58).
Role of the funding source
The sponsor of the study had no role in study design, data
collection, data analysis, data interpretation, or writing the report.
RESULTS
Study subjects
The mean age of women with normal cytology was 37 years (range
17–63 years). The mean age of women with ACIS was 37.1 years
(range 23–55) and did not differ statistically from the age of
women with normal cytology. Women with invasive AdCx and
SCC had a mean age of 44.7 years (range 28–79 years) and 49 years
(range 27–88 years), respectively. Both for women with AdCx
(Po0.01) and SCC (Po0.01) the mean age was statistically
significantly increased compared to women with normal cytology
or ACIS.
Of the 1525 women with normal cytology, 268 (17.6%) were
diagnosed with a multiple hrHPV infection. Multiple infections
were also common in women with ACIS (13/61, 21.3%). Women
with invasive AdCx (5/70, 7.1%) and SCC (9/83, 10.8%) had a lower
prevalence of multiple hrHPV infections than women with either
normal cytology or a noninvasive lesion (P¼0.007).
HrHPV type-specific prevalence in women with normal
cytology
Table 1 displays the hrHPV type-specific prevalence in women
with normal cytology compared with cases of cervical cancer
(in situ). In women with normal cytology, HPV16 accounted for
30.0% of hrHPV positivity and HPV31 for 15.7%. Another 10.0% of
hrHPV infections in women with normal cytology involved HPV18
and 8.0% HPV45. Type-specific prevalence did not substantially
change when analysing women with single infections separately
(Table 1).
HrHPV type-specific prevalence in women with cervical
ACIS
In women with ACIS, HPV18 infections (66.2%) dominated. Of
the remaining hrHPV infections, HPV45 accounted for 6.2% of
infections, HPV16 for 33.8%, and HPV31 for 4.6% (Table 1). No
other single hrHPV infections were observed in ACIS. When cases
with single infections were analysed separately, type-specific
prevalence did not change substantially.
When analysing for individual types, women with ACIS were
statistically significantly more likely to carry HPV18 than
women with normal cytology (ORMH 21.8; 95% CI 11.9–39.8).
The prevalence of HPV16 was comparable between women with
normal cytology and women with ACIS. However, after excluding
HPV18-positive cases from the analyses, prevalence of HPV16 was
9.4 times as frequently present in cases with ACIS compared to
women with normal cytology (95% CI: 2.8–31.2). After excluding
both HPV16- and HPV18-positive cases, prevalence of HPV45 was
also statistically significantly increased in cases with ACIS (ORMH
14.0; 1.3–150.9). When cases with single infections were analysed
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All analyses were repeated when matching ACIS cases with normal
controls 10 years younger, but estimates were not affected (data
not shown). For none of the HPV types, OR varied with age (data
not shown).
HrHPV type-specific prevalence in women with cervical
adenocarcinoma
In women with AdCx, HPV18 infections (57.1%) displayed the
highest prevalence. Of the remaining hrHPV infections, HPV45
accounted for 11.4% of infections and HPV16 for 35.7% (Table 1).
When cases with single infections were analysed separately, type-
specific prevalence did not change substantially.
Results were comparable for women with ACIS and for women
with invasive AdCx since HPV16 prevalence was not different
between AdCx and normal cytology (ORMH 1.3; 95% CI 0.8–2.2)
and women having AdCx were more likely to be infected by HPV18
than women with normal cytology (ORMH 15.0; 95% CI 8.6–26.1).
After exclusion of HPV18-positive cases, both HPV16 and HPV45
were statistically significantly associated with AdCx (ORMH 6.6;
95% CI 2.8–16.0 and ORMH 4.3; 95% CI 1.7–10.6, respectively).
Results for single infections only were comparable (Table 1). All
analyses were repeated matching cases with AdCx with normal
controls 10 years younger, but estimates were not affected (data
not shown). For none of the HPV types, OR varied with age (data
not shown).
HrHPV type-specific prevalence in women with SCC
Compared with cervical AdCx and its precursor ACIS, results were
reversed for HPV16 and HPV18 in women with SCC. Women with
SCC had an increased prevalence of HPV16 infections (69.9%)
compared to HPV18 infections (12.0%). Compared to the cases
with cervical AdCx, SCC showed more diversity in types as only
HPV51, HPV52, HPV59, HPV66, and HPV68 did not occur at all in
the cases of SCC.
Women having SCC were significantly more likely to carry
HPV16 than women with normal cytology (ORMH 7.0; 95% CI 3.9–
12.4). Since HPV16 dominated in cases of SCC, analyses were
repeated after exclusion of HPV16. In these analyses women with
SCC were more likely to carry HPV18 infections than women
with normal cytology (ORMH 4.3; 95% CI 1.6–11.6). Again, we
investigated whether less prevalent types displayed type-specific
increases in prevalence as well by excluding both HPV16 and
HPV18 from the analyses. In multiple infections, both HPV 31 and
HPV39 were more frequently present in SCC than in normal
cytology after exclusion of both HPV16 and HPV18 coinfections
(ORMH 3.5; 95% CI 1.0–11.5, and ORMH 5.4; 95% CI 1.3–21.7,
respectively). However, the prevalence of these types was not
increased in single infections. Results for single infections were
comparable. After matching SCC cases with controls 10 years
younger, none of the estimates were affected appreciably (data not
shown). For none of the HPV types OR varied with age (data not
shown).
DISCUSSION
This study on the distribution of 14 hrHPV types revealed marked
differences between cervical adenocarcinoma and its precursors,
and SCC. The prevalence of HPV16 is increased in SCC compared
to normal cytology, whereas HPV18 is more prevalent in
adenocarcinoma and its precursor. However, when accounting
Table 1 HrHPV type-specific prevalence in adenocarcinoma and its precursors and squamous cell carcinoma vs normal cytology - single infections and
single and multiple infections combined
Type Normal N¼1467 ACIS N¼65 AdCx N¼70 SCC N¼83 Normal vs ACIS Normal vs AdCx Normal vs SCC
Multiple
a N (%) N (%) N (%) N (%)
16 440 (30.0) 22 (33.8) 25 (35.7) 58 (69.9) 1.3 (0.7–2.2) 1.3 (0.8–2.2) 7.0 (3.9–12.4)
18 146 (10.0) 43 (66.2) 40 (57.1) 10 (12.0) 21.8 (11.9–39.8) 15.0 (8.6–26.1) 1.3 (0.6–2.8)
31 230 (15.7) 3 (4.6) — 6 (7.2) — — —
33 88 (6.0) — — 3 (3.6) — — —
35 74 (5.0) — — 2 (2.4) — — —
39 70 (4.8) — 1 (1.4) 4 (4.8) — — 1.5 (0.5–4.3)
45 118 (8.0) 4 (6.2) 8 (11.4) 5 (6.0) — 1.6 (0.8–3.5) —
51 98 (6.7) 1 (1.5) — — — — —
52 92 (6.3) — 1 (1.4) — — — —
56 134 (9.1) — — 2 (2.4) — — —
58 93 (6.3) — — 2 (2.4) — — —
59 43 (2.9) — — — — — —
66 100 (6.8) 1 (1.5) — — — — —
68 24 (1.6) — — — — — —
Single N¼1221 N¼48 N¼65 N¼74
16 344 (28.2) 14 (29.2) 22 (33.8) 55 (74.3) 1.0 (0.5–1.9) 1.3 (0.7–2.2) 9.2 (4.9–17.3)
18 108 (8.8) 31 (64.6) 36 (55.4) 8 (10.8) 69.4 (20.8–231.8) 15.8 (8.8–28.4) 1.5 (0.6–3.3)
31 170 (13.9) 1 (2.1) — 3 (4.1) — — —
33 66 (5.4) — — 1 (1.4) — — —
35 48 (3.9) — — — — — —
39 37 (3.0) — 1 (1.5) 1 (1.4) — — —
45 81 (6.6) 2 (4.2) 6 (9.2) 4 (5.4) — 1.5 (0.6–3.2) —
51 60 (4.9) — — — — — —
52 57 (4.7) — — — — — —
56 91 (7.5) — — — — — —
58 60 (4.9) — — 1 (1.4) — — —
59 31 (2.5) — — — — — —
66 59 (4.8) — — — — — —
68 9 (0.7) — — — — — —
Normal indicates normal cytology; ACIS indicates adenocarcinoma in situ; AdCx indicates adenocarcinoma; SCC indicates squamous cell carcinoma. Analyses are adjusted for age
in 5-year strata.
aMultiple and single infections combined.
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and HPV45 are also associated with adenocarcinoma and its
precursors, and HPV18 is associated with SCC as well. These data
suggest that within the group of high-risk types of which the
association with cervical cancer has already been established
beyond any doubt (Munoz et al, 2003), infections with either
HPV16, HPV18, or HPV45 confer a preferential risk to develop a
malignancy of the uterine cervix.
Some methodological aspects of this study need to be discussed.
Firstly, we compared cross-sectional data of women with normal
cytology obtained from the POBASCAM trial with retrospectively
collected cases of cervical cancer. This approach may have biased
our estimates of risk associated with specific hrHPV types. Women
with cervical cancer were on average older than the women with
normal cytology, and age has been shown to be associated with
hrHPV type-specific prevalence (Castle et al, 2005a). We used two
methods for to correct for the age difference. Firstly, we analysed
our data stratified in age categories. Secondly, a potential source of
bias may be that it takes at least 8–10 years to develop invasive
carcinoma of the cervix (van Oortmarssen and Habbema, 1995;
Zielinski et al, 2001). Women with cancer may have contracted an
hrHPV infection 10 years before they were diagnosed with cancer.
We repeated the analyses matching cases of cancer with normal
controls 10 years younger, and our estimates were not affected,
indicating the robustness of our data. Also, we defined women with
normal cytology as women having a screening smear diagnosed as
normal without either histologically or cytologically diagnosed
lesions in the 2 years preceding the screening smear. In the
Dutch screening programme, these women are considered to be
free of cervical disease, and they will not be called for
cervical screening for the next 5 years (van Ballegooijen and
Hermens, 2000). However, our population with normal cytology
may have contained a small number of women with either an
underlying high-grade lesion or who may develop a high-grade
lesion during follow-up. This diagnostic bias would have a diluting
effect on the risk estimates obtained by our study, as hrHPV
prevalence in the normal population would have resembled the
cervical lesion cases more closely. A strong point of our cross-
sectional approach is that we were able to use a reference group
of women with normal cytology taken from the same geographic
region as cases with cervical cancer. In contrast, other studies
relating hrHPV prevalence to histological type have relied on
pooling of data obtained from worldwide studies to provide
estimates of hrHPV prevalence in cancer and its precursor stages
and regional variations in type-specific prevalence may have
affected comparisons in these studies (Clifford et al, 2003a,b,
2005).
Thirdly, we have performed a type-specific E7 PCR in women
with carcinoma in order to diagnose integrated hrHPV infections,
whereas women with normal cytology were not evaluated using the
type-specific PCR. This may have resulted in a confirmation bias in
the diagnosis of hrHPV infections, as integrated hrHPV infections
in women with normal cytology may not have been diagnosed.
However, integration of the hrHPV occurs late in the progression
from normal epithelium to carcinoma, and viral integration is
extremely rare in a population of women with normal cytology
(Munoz et al, 2003). Therefore, we do not consider our approach
biased.
In addition to other studies demonstrating that adenocarcino-
mas are more often HPV18 positive than HPV16 positive (Pilch
et al, 2001; Schwartz et al, 2001; Altekruse et al, 2003; Burk et al,
2003; Clifford et al, 2003b; Huang et al, 2004), we have now shown
that when comparing invasive adenocarcinoma cases to cytologi-
cally normal controls, the ORMH is only 1.3 for HPV16 and 15.0 for
HPV18. Conversely, when comparing invasive SCC cases to normal
controls, ORMH is 7.0 for HPV16 and only 1.3 for HPV18. This
suggests that HPV16 and HPV18 are associated with a preferential
risk compared to the other high-risk types of hrHPV for the
development of either SCC or adenocarcinoma. Combining our
analyses both including HPV18 and excluding HPV18, our data
suggest that HPV18 is mainly a risk factor for the development of
adenocarcinoma whereas the highly aggressive HPV16 is asso-
ciated with both SCC and adenocarcinoma. Alternatively, HPV16
and HPV18 might preferentially induce differentiation in either
squamous or columnar direction respectively after infection of
epithelial stem cells localised in the basal layer of the epithelium.
The hrHPV types tested for in this study other than HPV16,
HPV18, and HPV45, did not reveal an increased prevalence in
either histological subtype of cervical cancer, suggesting that the
other types all pose a similar relatively low risk of progression to
cancer. This also includes HPV33, which is prevalent in lesions
XCIN2 (Bulkmans et al, 2005). However, a plausible explanation
might be that HPV33 has the potential to induce high-grade CIN
lesions relatively easy, whereas its capacity to induce progression
from high-grade CIN to invasive carcinoma might be relatively low
(Bulkmans et al, 2005).
What are the consequences of our findings for cervical
screening? Recently, it was shown that both HPV16 and HPV18
infections in women with normal cytology are associated with an
increased 10-year absolute risk for high-grade lesions and cervical
cancer (Khan et al, 2005). However, two other recently published
studies did not demonstrate an association of HPV18 with
cytological abnormalities and high-grade histological lesions
in either short-term follow-up or in a cross-sectional design
(Bulkmans et al, 2005; Castle et al, 2005b). These data suggest that
HPV18 infections, which we have shown to be preferentially
increased in prevalence in cervical adenocarcinomas, either do not
induce cervical lesions diagnosed as abnormal cytologically or
that cervical lesions associated with HPV18 are not diagnosed
as a result of sampling error, since these lesions are more often
localised high in the endocervical canal (Woodman et al, 2003).
Whatever the cause, our results show that HPV18 has a preferential
risk for AdCx and ACIS. Being aware of this association should
warrant a less expectant attitude for women with persistent HPV18
infections and normal cytology to refer women to colposcopically
mediated biopsies and endocervical sampling in case of a normal
transformation zone.
In conclusion, we have shown that HPV16, HPV18, and HPV45
display an increased prevalence in cervical cancer compared to
cytologically normal smears. HPV16 confers the greatest risk for
SCC and HPV18 for adenocarcinoma of the cervix. These data
strongly argue for hrHPV type-specific risk stratification of women
with normal cytology and a positive hrHPV test participating in
cervical screening programmes.
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